Securities code: Sansure Biotech Inc(688289) securities abbreviation: Sansure Biotech Inc(688289) Announcement No.: 2022032 Sansure Biotech Inc(688289)
Announcement on confirmation of daily connected transactions in 2021 and expected daily connected transactions in 2022
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
Whether it needs to be submitted to the general meeting of shareholders for deliberation: no
Impact of daily related party transactions on the company: the confirmation of daily related party transactions in 2021 and the expected daily related party transactions in 2022 are based on the actual needs of Sansure Biotech Inc(688289) (hereinafter referred to as ” Sansure Biotech Inc(688289) ” or “the company”) in daily business activities, follow the principles of fair and just market, and the transaction price is determined through negotiation based on the market price, The payment arrangement and settlement method are implemented in accordance with the rules and requirements of the company’s transactions with other customers or suppliers. There is no behavior that damages the interests of the company and all shareholders, especially the minority shareholders, and will not affect the operation and independence of the company.
1、 Basic information of daily connected transactions
(I) review procedures for the performance of daily connected transactions
The company held the third meeting of the first board of directors in 2022 on April 18, 2022, considered and passed the proposal on confirmation of daily connected transactions in 2021 and expected daily connected transactions in 2022, The daily transactions between the company and Hunan Dasheng Chongyi Biotechnology Co., Ltd. (hereinafter referred to as “Dasheng Chongyi”) and Shenzhen Zhenmai Biotechnology Co., Ltd. (hereinafter referred to as “Zhenmai biotechnology”) in 2021 were confirmed, and the total amount of daily related party transactions in 2022 is expected to be 38 million yuan. Mr. Dai Lizhong, a related director, has withdrawn from voting. The proposal has been unanimously deliberated and adopted by the non related directors present at the meeting, and the deliberation procedures comply with the provisions of relevant laws and regulations.
The independent directors of the company expressed their independent opinions on the proposal. The independent directors believe that the actual situation of the company’s daily related party transactions in 2021 is different from the expected situation, which is consistent with the actual situation of the company. The daily related party transactions that have occurred in 2021 are fair and reasonable, and there is no damage to the interests of the company and shareholders. The company’s prediction of daily connected transactions in 2022 is based on the actual needs of the company’s daily business activities, and the connected transactions are the interests of minority shareholders. The deliberation and voting procedures of relevant proposals comply with the provisions of relevant laws, regulations and the articles of association, and agree with the confirmation of the company’s daily connected transactions in 2021 and the prediction of daily connected transactions in 2022.
According to the relevant provisions of the Listing Rules of Shanghai Stock Exchange, the articles of association and other relevant regulations, the confirmation of daily connected transactions in 2021 and the expected daily connected transactions in 2022 are within the approval authority of the board of directors of the company and do not need to be submitted to the general meeting of shareholders for deliberation.
(II) estimated amount and category of daily connected transactions in 2022
Currency: RMB unit: 10000 yuan
From the beginning of 2022 to 2021, the expected related party transactions in 2022 account for the disclosure date and degree of relevance of the same kind in 2022, the actual amount of the same kind in 2022 and the estimated distribution business ratio of the related party of the easy content in 2021. The cumulative amount of the occurred gold business is compared with the actual amount of the year (%) Reasons for the large difference in the amount of students
Sell Shengchong medicine to related Hunan Dafang
Products, biology 300.00 0.08 3.82 460.22 0.10-
Commodity Technology Co., Ltd
company
Shenzhen City
Purchase shopping technology from the related party of zhenmaisheng gene sequencing 250000 100 8.64 620.35 100 customs business development commodities Co., Ltd
department
Due to the severe situation of epidemic prevention and control outside China recently, The relevant inspection of Hunan large company and the delivery of Guan Shengchong’s medical test products to the head of the Service Technology Co., Ltd. of biologics 100000 100427.64 362.08 100 with a significant increase in sales volume, The capacity of existing property companies is insufficient, Therefore, the demand for relevant services of the related party has increased
Total – 380000 – 440.10144265-
Note: the proportion of the expected amount in 2022 in similar business is the proportion in 2022; The proportion of actual amount in similar business in 2021 is compared with similar business in 2021.
(III) implementation of daily connected transactions in 2021
Currency: RMB unit: 10000 yuan
Content of related party transactions the reason for the large difference between the actual estimated amount of the related party in the previous year (previous) and the actual accrued amount in the previous year (previous)
Sales to related parties 100000 460.22-
Products and commodities
Inspection provided to related parties – 0.33-
Test service
Rental of house from related parties Hunan Dasheng 5.50 5.00-
House building pet medical creature
Technology Co., Ltd
Lending instrument company to related parties
Actuator 10.00 4.50-
Instruments lent by related parties 10.00 0.00-
Resale
Due to business needs, Shenzhen Zhencheng company purchased sequencer and related test article Technology Co., Ltd. – 620.35 agent from its related party purchaser maibio, It has been deliberated and approved by the general manager’s office meeting held by the company on August 1, 2021
Due to the company’s lack of production capacity, it provides labor outsourcing for Hunan Dasheng company and accepts related parties to provide pet medical biology – 362.08 technical services, The company’s Service Technology Co., Ltd. held the general manager’s office meeting on August 1, 2021
Shenzhen Zhenmai Biological Technology Co., Ltd. borrowed Yimai biological technology – 80.00 yuan from related parties for the company’s investment and was stationed in the director’s office within 12 months
Total – 102550153248-
Note: 45000 yuan of instruments borrowed from related parties and 800000 yuan of instruments borrowed from related parties are the amount incurred in 2021. As of December 31, 2021, relevant instruments have been returned.
2、 Basic information and relationship of related parties
(I) basic information of related parties
(1) Enterprise name: Hunan dashengchongyi Biotechnology Co., Ltd
Nature: limited liability company (invested or controlled by natural person)
Legal representative: Dai Lizhong
Registered capital: 30 million yuan
Date of establishment: March 12, 2021
Address and main office location: No. 301, No. 2, haipingyuan production plant, No. 229, Guyuan Road, high tech Industrial Development Zone, Changsha, Hunan
Main business: licensed items: operation of class III medical devices; Veterinary drug production; Veterinary drug management; Inspection and testing services; Animal diagnosis and treatment (items that must be approved according to law can only be carried out after being approved by relevant departments, and the specific business items shall be subject to the approval documents or licenses of relevant departments) general items: technical services, technical development, technical consultation, technical exchange, technology transfer and technology promotion; Sales of class I medical devices; Sales of class II medical devices; Information consulting services (excluding licensed information consulting services); Technology import and export; Import and export of goods; Instrument sales; Sales of veterinary special instruments; Information technology consulting services; Agricultural scientific research and experimental development; Retail of pet food and supplies; Sales of experimental and analytical instruments; Labor services (excluding labor dispatch) (except for the items that must be approved according to law, carry out business activities independently according to law with the business license).
Major shareholder: held by Zhuhai Weiyu Tongyi management consulting enterprise (limited partnership)
